Clinical Trials Sponsored by 4SC

Total 203 results

4SC AG

Completed

A Phase 1, Open-label Study of the Absorption, Metabolism, Excretion of [14C]-Resminostat

Mycosis Fungoides | Sezary Syndrome | Cutaneous T Cell Lymphoma

United Kingdom
4SC AG

Completed

Oral Histone Deacetylase Inhibitor 4SC-202 in Patients With Advanced Hematologic Malignancies (TOPAS)

Advanced Hematologic Malignancies

Germany
4SC AG

Completed

4SC-201 (Resminostat) and Sorafenib in Advanced Hepatocellular Carcinoma (Shelter)

Hepatocellular Carcinoma

Germany, Italy
4SC AG

Completed

Single Dose Study With 4SC-203 in Healthy Volunteers

Acute Myeloid Leukemia

Germany
4SC AG

Active, not recruiting

Domatinostat in Combination With Avelumab in Patients With Advanced Merkel Cell Carcinoma Progressing on Anti-PD-(L)1 (MERKLIN2)

Merkel Cell Carcinoma

Spain, Netherlands, Belgium, Germany, France, Italy
4SC AG

Completed

4SC-201 (Resminostat) in Advanced Colorectal Carcinoma (SHORE)

Advanced Colorectal Carcinoma

Germany
4SC AG

Completed

Resminostat (4SC-201) in Relapsed or Refractory Hodgkin's Lymphoma (SAPHIRE)

Hodgkin's Lymphoma

Poland, Czech Republic, Romania
4SC AG

Completed

SC12267 (4SC-101) in Combination With Methotrexate in Patients With Rheumatoid Arthritis (COMPONENT)

Rheumatoid Arthritis

Bulgaria, Czech Republic, Poland, Romania
4SC AG

Completed

SC12267 (4SC-101) for Treatment of Patients With Inflammatory Bowel Disease (ENTRANCE)

Inflammatory Bowel Disease (IBD)

Germany, Bulgaria, Romania
4SC AG

Active, not recruiting

Resminostat for Maintenance Treatment of Patients With Advanced Stage Mycosis Fungoides (MF) or Sézary Syndrome (SS) (RESMAIN)

Lymphoma, T-Cell, Cutaneous | Mycosis Fungoides | Sezary Syndrome

Austria, Spain, Germany, United Kingdom, France, Belgium, Japan, Switzerland, Italy, Poland, Netherlands, Greece
4SC AG

Completed

4SC-202 in Combination With Pembrolizumab in Patients Primary Refractory/Non-responding to Prior Anti-PD-1 Therapy (SENSITIZE)

Malignant Melanoma

Germany, Italy
4SC AG

Completed

Open Label, Dose Escalation Trial of Oral Eg5 Kinesin-spindle Inhibitor 4SC-205 in Patients With Advanced Malignancies (AEGIS)

Malignant Lymphomas | Advanced and Incurable Solid Tumors

Germany
The Netherlands Cancer Institute
4SC

Active, not recruiting

Multicenter Phase 1b Trial Testing the Neoadjuvant Combination of Domatinostat, Nivolumab and Ipilimumab in IFN-gamma Signature-low and IFN-gamma Signature-high RECIST 1.1-measurable Stage III Cutaneous or Unknown Primary Melanoma (DONIMI)

Malignant Melanoma Stage III

Netherlands
The Netherlands Cancer Institute
4SC AG

Active, not recruiting

Pre-operative Immunotherapy in Stage II-III Urothelial Cancer (TURANDOT)

Urothelial Carcinoma

Netherlands
4SC AG
Merck KGaA, Darmstadt, Germany

Withdrawn

Domatinostat in Combination With Avelumab in Patients With Treatment-naïve Metastatic Merkel Cell Carcinoma (MERKLIN 1)

Merkel Cell Carcinoma
Diabetis JSC

Recruiting

FeetSee Thermal Images Collection Protocol

Diabetic Foot

Lithuania
ASC Therapeutics

Recruiting

ASC618 Gene Therapy in Hemophilia A Patients

Hemophilia A

United States
Efferon JSC

Recruiting

Combination of Cytokine Hemosorption and High-volume Hemofiltration in Acute Pancreatitis

Acute Pancreatitis Without Necrosis or Infection

Russian Federation
Efferon JSC

Recruiting

Selective Lipopolysaccharide Hemosorption in Maternal Sepsis (MINERVA)

Maternal sepsIs

Russian Federation
ASC Therapeutics

Not yet recruiting

ASC930 in Patients With Steroid-Refractory Acute Graft Versus Host Disease (SR-aGVHD)

Acute-graft-versus-host Disease
Efferon JSC

Completed

Hemoperfusion Efferon СT for the Treatment of Patients With Acute Pancreatitis

Acute Pancreatitis With Uninfected Necrosis, Unspecified

Russian Federation
Efferon JSC

Completed

Hemoperfusion With the Efferon CT Extracorporeal Adsorbers in Patients With Severe Covid-19

COVID-19

Russian Federation
Efferon JSC

Completed

Efferon LPS Hemoperfusion for Treatment of Patients With Septic Shock

Septic Shock

Russian Federation
Atatürk University
MSc Reyhan YALÇIN; MSc Meral Güven

Completed

Pain in Newborn Heel Blood Collection

Pain, Acute | Infant, Newborn, Disease

Turkey
Valenta Pharm JSC

Not yet recruiting

Comparative Pharmacodynamics and Pharmacodynamics Equivalence of Antareit 800 mg/10 ml Oral Suspension and Riopan 800 mg Chewable Tablets in Healthy Volunteers

Heartburn | Acid-dependent Diseases of the Gastrointestinal Tract | Symptomatic Treatment of Gastric and Duodenal Ulcers

Russian Federation
Valenta Pharm JSC

Not yet recruiting

Pharmacokinetics and Bioequivalence of Aterixen 100 mg Tablets and Aterixen 100 mg Film-coated Tablets in Healthy Volunteers

Viral Infection COVID-19

Russian Federation
Valenta Pharm JSC

Completed

A Study to Evaluate the Safety and Efficacy of XC221 in Patients With Uncomplicated Influenza or Other Acute Viral Upper Respiratory Infections

Influenza | Respiratory Viral Infection

Russian Federation
Valenta Pharm JSC

Completed

Safety and Pharmacokinetics of Dioxidin, Solution for Topical and External Use, 0.25 mg/ml and Dioxidin, Solution for Infusion and External Use, 5 mg/ml in Healthy Volunteers

Infections

Russian Federation
Valenta Pharm JSC

Completed

Pharmacokinetics and Bioequivalence of Molnupiravir, 200 mg Capsules and Lagevrio, 200 mg Capsules in Healthy Volunteers

COVID-19 | Viral Infection

Russian Federation
Valenta Pharm JSC

Completed

Efficacy and Safety of Ingavirin®, 90 mg Capsules in Patients With COVID-19

COVID-19

Russian Federation
Valenta Pharm JSC

Completed

Pharmacokinetics and Bioequivalence of Doxylamine + Pyridoxine, Film-coated, Enteric-soluble Tablets, and Diclectin, Delayed Release Tablets, in Healthy Volunteers

Nausea | Pregnancy Related

Russian Federation
Valenta Pharm JSC

Completed

A Study of the Efficacy and Safety of Ranquilon Tablets in Patients With Anxiety in Neurasthenia and Adjustment Disorders

Anxiety | Adjustment Disorders | Neurasthenia

Russian Federation
Valenta Pharm JSC

Completed

Efficacy and Safety of XC8, Film-coated Tablets, 10 mg in Patients With Dry Non-productive Cough Against Acute Respiratory Viral Infection

Influenza, Human | Common Cold | Acute Respiratory Infection

Russian Federation
Valenta Pharm JSC

Completed

Efficacy and Safety Study of Ingavirin® to Treat Influenza and Acute Respiratory Viral Infections in Patients 13-17 y.o.

Influenza, Human | Common Cold | Acute Respiratory Infection | Viral Infection

Russian Federation
Valenta Pharm JSC

Completed

Efficacy and Safety Study of Ingavirin® 90 mg Once Daily to Treat Influenza and Other Acute Viral Infections in Adults

Influenza, Human | Common Cold | Acute Respiratory Infection

Russian Federation
DSC Services, s.r.o.

Unknown

Monitoring of Allergic and Asthmatic Symptoms in Patients Taking Dietary Supplements Joalis Bambi Bronchi and Joalis Bambi Analerg

Children

Czech Republic
Valenta Pharm JSC

Recruiting

Efficacy and Safety of Vespireit, Sustained-release Tablets, in Patients With Autonomic Dysfunction Syndrome Accompanied by Functional Vertigo

Vertigo | Autonomic Dysfunction

Russian Federation
Valenta Pharm JSC

Recruiting

Safety, Tolerability and Pharmacokinetics of 4-MUST, Tablets, 128 mg (Valenta Pharm JSC) During Single and Multiple Oral Administration in Healthy Volunteers

Cholecystitis

Russian Federation
Valenta Pharm JSC

Completed

Efficacy and Safety of Dioxidin Versus Miramistin in Superficial Pyoderma

Pyoderma

Russian Federation
Valenta Pharm JSC

Completed

Efficacy and Safety of Ingavirin®, Syrup, 30 mg/5 ml, in Children With Influenza and Other Acute Respiratory Viral Infections

Influenza, Human | Common Cold | Acute Respiratory Infection

Russian Federation
Valenta Pharm JSC

Completed

Study of the Effect of Food Intake on the Bioavailability of XC221 100 mg Tablets

Healthy

Russian Federation
Valenta Pharm JSC

Recruiting

Efficacy and Safety of XC8, Film-coated Tablets, in Children With Acute Respiratory Viral Infections

Acute Respiratory Infection

Russian Federation
Valenta Pharm JSC

Recruiting

Food Effect on the Bioavailability of 4-MUST, Tablets, 128 mg

Cholecystitis

Russian Federation
Valenta Pharm JSC

Recruiting

Pharmacokinetics and Bioequivalence of Doxylamine+Pyridoxine and Diclectin

Nausea

Russian Federation
Valenta Pharm JSC

Recruiting

Efficacy and Safety of Ingavirin®, Capsules, 60 mg, in Children With Influenza and Other Acute Respiratory Viral Infections

Influenza, Human | Common Cold | Acute Respiratory Infection

Russian Federation
Valenta Pharm JSC

Completed

Pharmacokinetics and Bioequivalence of XC8 10 mg and 40 mg Tablets in Fasted Volunteers

Influenza | Respiratory Viral Infection

Russian Federation
Valenta Pharm JSC

Completed

A Study to Evaluate the Safety, Tolerability and Efficacy of XC221 in Patients With Uncomplicated Influenza or Other Acute Viral Upper Respiratory Infections

Influenza | Viral Respiratory Infection | Acute Viral Upper Respiratory Infections

Russian Federation
Valenta Pharm JSC

Completed

Efficacy and Safety of XC8, Film-coated Tablets, 40 mg in Patients With Dry Non-productive Cough Against Acute Respiratory Viral Infection

Influenza, Human | Common Cold | Acute Respiratory Infection

Russian Federation
Valenta Pharm JSC

Completed

Study of the Effect of Food Intake on the Bioavailability of XC8 10 mg Film-coated Tablets

Healthy

Russian Federation
Valenta Pharm JSC

Completed

Efficacy and Safety of Buspirone, Sustained-release Tablets, 15 mg in Patients With Autonomic Dysfunction Syndrome Accompanied by Vertigo

Vertigo | Autonomic Dysfunction

Russian Federation

3

Subscribe